Shree Dhanvantary Pharmaceutical Analysis and Research Centre (SDPARC) is a contract research organization established in 2006 and is managed by RIBOSOME PHARMA PVT. LTD., Surat. SDPARC offers a wide range of analytical & research services for small, medium and large scale pharmaceutical, ayurvedic, bulk drug, chemical, food and cosmetic industries. The centre is approved by the Food and Drug Control Administration (FDCA), Gujarat state as a public testing laboratory and is spread over 8,000 sq. ft. area.
CTI BioPharma Corp. announced that the Company received written communication from the U.S. Food and Drug Administration (FDA) on February 4, 2016, that the FDA has placed a partial clinical hold on the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. This clinical hold impacts part of the clinical work currently being conducted under the IND and will also affect planned clinical trials.